D. Berton (Porto Alegre (RS), Brazil), D. Halpin (Exeter, United Kingdom)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
A retrospective evaluation of lung function and exacerbations in COPD patients-RETRIEVE study.
S. Tryfon (Thessaloniki, Greece), C. Babalis (Serres, Greece), A. Skliris (Corfu, Greece), P. Papanastasiou (Pikermi, Greece), M. Bertoli (Pikermi, Greece)
|   |
Characteristics and treatment pathways of patients with COPD receiving a long-acting muscarinic antagonist/long-acting ß2-agonist (LABA/LAMA) in the UK
G. Requena (Brentford, Middlesex, United Kingdom), V. Banks (Bollington, Cheshire, United Kingdom), A. Czira (Brentford, Middlesex, United Kingdom), R. Wood (Bollington, Cheshire, United Kingdom), T. Tritton (Bollington, Cheshire, United Kingdom), E. Ha (Bollington, Cheshire, United Kingdom), R. Wild (Bollington, Cheshire, United Kingdom), C. Compton (Brentford, Middlesex, United Kingdom), A. Ismaila (Pennsylvania, PA, United States of America)
| |
REALizing and improving management of COPD in China: A prospective observational study
T. Yang (Beijing, China), B. Cai (Beijing, China), B. Cao (Beijing, China), J. Kang (Shenyang , China), F. Wen (Chengdu, China), Y. Chen (Beijing , China), W. Jian (Guangzhou, China), C. Wang (Beijing , China), H. Shang (Shanghai, China), Y. Fei (Shanghai, China)
| |
Long Acting B-2 Agonists (LABA) or Anticholinergics (LAMA): Which one is more efficient in Group A COPD Patients?
M. Turan (Izmir, Turkey), N. Ogan (Ankara, Turkey), F. Bozkus (Kahramanmaras, Turkey), N. Sarioglu (Balikesir, Turkey), P. Turan (Izmir, Turkey), C. Satici (Istanbul, Turkey)
| |
Comparison of initial drug treatment of incident COPD patients with German treatment guidelines
C. Vogelmeier (Marburg, Germany), M. Hechtner (Ingelheim, Germany), N. Picker (Wismar, Germany), A. Neitz (Ingelheim, Germany), P. Hofmann (Ingelheim, Germany), U. Maywald (Dresden, Germany), T. Wilke (Wismar, Germany), R. Buhl (Mainz, Germany)
| |
No impact of statins on time to first COPD exacerbation or all-cause mortality
N. Godtfredsen (Hvidovre, Denmark), M. Damkjær (Hvidovre, Denmark), K. Håkansson (Hvidovre, Denmark), T. Kallemose (Hvidovre, Denmark), C. Ulrik (Hvidovre, Denmark)
| |
Post Marketing Surveillance to evaluate the safety and effectiveness of Umeclidinuim Bromide in Korean patients with COPD
H. Choi (Seoul, Republic of Korea), S. Min (Seoul, Republic of Korea)
| |
Real-world treatment of incident COPD patients in Germany
R. Buhl (Mainz, Germany), N. Picker (Wismar, Germany), M. Hechtner (Ingelheim, Germany), A. Kondla (Ingelheim, Germany), P. Hoffman (Ingelheim, Germany), U. Maywald (Dresden, Germany), T. Wilke (Wismar, Germany), C. Vogelmeier (Marburg, Germany)
| |
Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid
C. Rhee (Seoul, Republic of Korea), Y. Kim (Chuncheon, Republic of Korea), Y. Hwang (Anyang, Republic of Korea), K. Yoo (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), K. Jung (Seoul, Republic of Korea), Y. Park (Seoul, Republic of Korea)
| |
Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK
A. Czira (Brentford, Middlesex, United Kingdom), V. Banks (Bollington, Cheshire, United Kingdom), G. Requena (Brentford, Middlesex, United Kingdom), R. Wood (Bollington, Cheshire, United Kingdom), T. Tritton (Bollington, Cheshire, United Kingdom), E. Ha (Bollington, Cheshire, United Kingdom), R. Wild (Bollington, Cheshire, United Kingdom), C. Compton (Brentford, Middlesex, United Kingdom), A. Ismaila (Collegeville, PA, United States of America)
| |
Risk of Haemophilus Influenzae Infection in Patients with Chronic Obstructive Pulmonary Disease Using Inhaled Corticosteroids: A Cohort Study of 23,789 Outpatients.
R. ul mohsin (Copenhagen, Denmark), P. Sivapalan (Copenhagen, Denmark), J. Eklöf (Copenhagen, Denmark), M. Isam Saeed (Copenhagen, Denmark), T. Ingebrigtsen (Roskilde, Denmark), S. Poulsen (Copenhagen, Denmark), Z. Harboe (Hillerød, Denmark), K. Iversen (Copenhagen, Denmark), J. Bangsborg (Copenhagen, Denmark), J. Jarløv (Copenhagen, Denmark), J. Boel (Copenhagen, Denmark), C. Andersen (Copenhagen, Denmark), H. Calum (Copenhagen, Denmark), R. Dessau (Copenhagen, Denmark), J. Stæhr Jensen (Copenhagen, Denmark)
| |
Investigating the drivers for COPD treatment decisions
A. Ferreira (Coimbra, Portugal), P. Bakke (Bergen, Norway), H. Ekroos (Porvoo, Finland), S. Soulard (Amsterdam, Netherlands), M. Haaksma-Herczegh (Amsterdam, Netherlands), M. MESTRES-SIMON (Barcelona, Spain), M. Águila-Fuentes (Barcelona, Spain), J. Kocks (Groningen, Netherlands), O. Van Schayck (Maastricht, Netherlands), N. Tzanakis (Creete, Greece), D. Cataldo (Liège, Belgium)
| |
Treatment patterns of patients with chronic obstructive pulmonary disease (COPD) in Ontario, Canada
K. Johnston (Vancouver, Canada), C. Qian (Vancouver, Canada), M. Soliman (Mississauga, Canada), S. Noorduyn (Mississauga, Canada), E. Penz (Saskatoon, Canada)
| |